SYSTEMIC SCLEROSIS

This early-stage study tests a new treatment called ALLO-329, made from donor immune cells engineered to attack two targets (CD19 and CD70) involved in autoimmune diseases. It is for adults with lupus (with or without kidney inflammation), myositis, or scleroderma. The main goals…

This study tests a new treatment called anti-CD19/BCMA universal CAR-T cells for people with severe autoimmune diseases like rheumatoid arthritis, lupus, and scleroderma. The therapy uses specially engineered immune cells to target and reduce harmful B cells that drive the diseas…

This early-phase trial tests a new treatment called AZD0120 for adults with three autoimmune diseases: systemic sclerosis, idiopathic inflammatory myopathies, and difficult-to-treat rheumatoid arthritis. AZD0120 uses a patient's own immune cells that are modified in a lab to targ…

This study tests a new treatment for people with autoimmune disorders like systemic sclerosis, lupus, and lupus nephritis. It combines a special immune cell therapy (AD-PluReceptor-NK cells) with a drug called tafasitamab and chemotherapy. The goal is to find a safe dose and see …

This study tests whether adding two immune-targeting drugs (belimumab and rituximab) to standard treatment can improve skin hardening in people with early, severe scleroderma. About 30 adults will receive either the combination or placebo, while all continue their usual medicatio…

This study tests a new treatment for people with lupus, scleroderma, dermatomyositis, or polymyositis. It uses the patient's own immune cells, which are modified in a lab to find and attack faulty B cells that drive the disease. The goal is to safely control the autoimmune attack…

This early-stage trial tests a one-time treatment called CABA-201, made from a patient's own immune cells, for systemic sclerosis (scleroderma). The goal is to see if it is safe and can control the disease by targeting and removing faulty B cells. About 12 adults with active, mod…

This early-stage study is testing a one-time treatment called CTX112, made from donor immune cells edited with CRISPR technology. It aims to see if it is safe and can help adults with severe lupus, scleroderma, or myositis that haven't improved with standard treatments. About 80 …

This early-phase study tests a new treatment using a patient's own immune cells, modified to target and attack harmful immune cells causing autoimmune diseases like lupus and scleroderma. About 20 adults aged 18 to 70 will receive CD19 or CD19-BCMA CAR-T cells. The main goal is t…

This study tests a stem cell transplant using the patient's own blood cells for young people (ages 8-24) with severe scleroderma that hasn't improved with standard treatments. The goal is to see if this high-dose therapy is safe and can control the disease better than current med…

This early-stage study tests a new cell treatment called YTS109 in 18 adults with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard therapies. Participants receive a single infusion of these specially designed cells. The main goal is to che…

This study tests a new treatment using specially engineered immune cells from cord blood to target and calm overactive immune cells in people with severe lupus, scleroderma, or Sjogren's syndrome with lung complications. The main goal is to check safety, especially any serious si…

This early-stage study tests a new treatment called CC-97540, which uses a patient's own immune cells engineered to target and destroy faulty immune cells causing disease. It is for people with severe forms of lupus, myositis, scleroderma, or rheumatoid arthritis that have not re…

This pilot study tests whether a personalized home respiratory exercise program is practical for people with systemic sclerosis (scleroderma) who have early lung disease. Fifteen participants will do one supervised session then follow a 3-month home program. The goal is to see if…

This study aims to better understand systemic sclerosis, a rare disease that causes hardening of the skin and organs. Researchers will analyze skin and blood samples from 40 adults with the condition to see how different cell types interact. The goal is to find new clues that cou…

This study follows 500 adults with systemic sclerosis (a rare autoimmune disease causing skin thickening and organ damage) over 5 years. Researchers will track how the disease naturally progresses by monitoring key complications like lung and kidney problems. They will also colle…

This study is building a large database and sample bank from 5,000 adults with rheumatic diseases like rheumatoid arthritis, lupus, and ankylosing spondylitis. Researchers will collect medical information and blood or tissue samples over time to find links between patient outcome…